Constitutive activity of glucagon receptor mutants

Molecular Endocrinology

Volumn 12, Issue 1, 1998, Pages 78-86

  Hjorth, Siv A ^a   Ørskov, Cathrine ^a   Schwartz, Thue W ^a  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON RECEPTOR;

AMINO TERMINAL SEQUENCE; ANIMAL CELL; ARTICLE; BINDING AFFINITY; DELETION MUTANT; DISSOCIATION CONSTANT; GLUCOSE BLOOD LEVEL; LIGAND BINDING; MUTAGENESIS; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR BINDING; RECEPTOR UPREGULATION;

ANIMALIA;

EID: 0031892559     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/mend.12.1.0045     Document Type: Article

References (41)

1. Ørskov C 1992 Glucagon-like peptide-1, a new hormone of the entero-insular axis. Diabetologia 35:701-711
2. Schwartz TW 1996 Molecular Structure of G-Protein Coupled Receptors. In: Foreman JC, Johansen T (eds) Textbook of Receptor Pharmacology. CRC Press, Boca Raton, FL, pp 65-84
3. Segre GV, Goldring SR 1993 Receptors for secretin, calcitonin, parathyroid hormone (PTH)/PTH-related peptide, vasoactive intestinal peptide, glucagon-like peptide 1, growth hormone-releasing hormone, and glucagon belong to a newly discovered G-protein-linked receptor family. Trends Endocrinol Metab 4:309-314
4. Laburthe M, Couvineau A, Gaudin P, Maoret J-J, Royer-Fessard C, Nicole P 1996 Receptors for VIP, PACAP, secretin, GRF, glucagon, GLP-1, and other members of their new family of G protein-linked receptors: structure-function relationship with special reference to the human VIP-1 receptor. Ann NY Acad Sci 805:94-109
5. Schwartz TW, Gether U, Schambye HT, Hjorth SA 1995 Molecular mechanism of action of non-peptide ligands for peptide receptors. Curr Pharmacol Design 1:325-342
6. Schwartz TW, Rosenkilde MM 1996 Is there a lock for all agonist keys in 7TM receptors? Trends Pharmacol Sci 17:213-216
7. Unson C, Cypess AM, Kim HN, Goldsmith PK, Carruthers CJL, Merrifield RB, Sakmar TP 1995 Characterization of deletion and truncation mutants of the rat glucagon receptor. J Biol Chem 270:27720-27727
8. Unson C, Cypess AM, Wu C-R, Goldsmith PK, Merrifield RB, Sakmar TP 1996 Antibodies against specific extracellular epitopes of the glucagon receptor block glucagon binding. Proc Natl Acad Sci USA 93:310-315
9. Stroop, SD, Kuestner, RE, Serwold, TS, Chen, L, Moore, EE 1995 Chimeric human calcitonin and glucagon receptors reveal two dissociable calcitonin interaction sites. Biochemistry 34:1050-1057
10. Buggy JJ, Livingston JN, Rabin DU, Yoo-Warren H 1995 Glucagon. glucagon-like peptide I receptor chimeras reveal domains that determine specificity of glucagon binding. J Biol Chem 270:7474-7478
11. Gelling RW, Wheeler MB, Xue J, Gymorey S, Nian C, Pederson RA, McIntosh CH 1997 Location of the domains involved in ligand binding and activation of the glucose-dependent insulinotropic polypeptide receptor. Endocrinology 138:2640-2643
12. Hjorth SA, Schwartz TW 1996 Glucagon and GLP-1: lessons from chimeric receptors and chimeric peptides. Acta Physiol Scand 157:343-345
13. Holtmann MH, Hadac EM, Miller LJ 1995 Critical contributions of amino-terminal extracellular domains in agonist binding and activation of secretin and vasoactive intestinal polypeptide receptors. J Biol Chem 270:14394-14398
14. Lee C, Gardella TJ, Abou-Samra A, Nussbaum SR, Segre GV, Potts JT, Kronenberg HM, Jüppner H 1994 Role of the extracellular regions of the parathyroid hormone (PTH)/PTH-related peptide receptor in hormone binding. Endocrinology 135:1488-1495
15. Gaudin P, Couvineau A, Maoret J-J, Royer-Fessard C, Laburthe M 1995 Mutational analysis of cysteine residues within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 211:901-908
16. Coughlin SR 1994 Expanding horizons for receptors coupled to G proteins: diversity and disease. Curr Topics Cell Biol 6:191-197
17. Chidiac P, Hebert TE, Valiquette M, Dennis M, Bouvier M 1994 Inverse agonist activity of β-adrenergic antagonists. Mol Pharmacol 45:490-499
18. Tiberi M, Caron M 1994 High agonist-independent activity is a distinguishing feature of the dopamine D1B receptor subtype. J Biol Chem 269:27925-27931
19. Samana P, Cotecchia S, Costa T, Lefkowitz RJ 1993 A Mutation-induced activated state of the β2-adrenergic receptor. J Biol Chem 268:4625-4636
20. 1B-adrenergic receptor by all amino acid substitutions at a single site. J Biol Chem 267:1430-1433
21. Robbins L, Nadeau JH, Johnson KR, Kelly MA, Roselli-Rehfuss L, Baack E, Mountjoy KG, Cone RD 1993 Pigmentation phenotypes of variant extension locus alleles result from point mutations that alter MSH receptor function. Cell 72:827-834
22. Nanevicz T, Wang L, Chen M, Ishii M, Coughlin SR 1996 Thrombin receptor activating mutations. J Biol Chem 271:702-706
23. Schipani E, Kruse K, Jüppner H 1995 A constitutively active mutant PTH-PTHrP receptor in Jansen-type metaphyseal chondrodysplasia. Science 268:98-100
24. Schipani E, Langman CB, Parfitt AM, Jensen GS, Kikuchi S, Kooh SW, Cole WG, Jüppner H 1996 Constitutively activated receptors for parathyroid hormone and parathyroid hormone-related peptide in Jansen-type metaphyseal chondrodysplasia. N Engl J Med 335:708-714
25. Grady T, Fickova M, Tager HS, Trivedi D, Hruby VJ 1987 Stimulation and inhibition of cAMP accumulation by glucagon in canine hepatocytes. J Biol Chem 262: 15514-15520
26. Unson CG, Macdonald D, Ray K, Durrah TL, Merrifield RB 1991 Position 9 replacement analogs of glucagon uncouple biological activity and receptor binding. J Biol Chem 266:2763-2766
27. Schipani E, Jensen GS, Pincus J, Nissenson RA, Gardella TJ, Jüppner H 1997 Constitutive activation of the cyclic adenosine 3′,5′-monophosphate signalling pathway by parathyroid hormone (PTH)/PTH-related peptide receptors mutated at the two loci for Jansen's metaphyseal chondrodysplasia. Mol Endocrinol 11:851-858
28. 1B-adrenergic receptor: role of highly conserved polar amino acids in receptor activation. EMBO J 15:3566-3578
29. Carruthers CJL, Unson CG, Kim HN, Sakmar TP 1994 Synthesis and expression of a gene for the rat glucagon receptor. J Biol Chem 269:29321-29328
30. Gaudin P, Couvineau A, Maoret J-J, Royer-Fessard C, Laburthe M 1995 Mutational analysis of cysteine residue within the extracellular domains of the human vasoactive intestinal peptide (VIP) 1 receptor identifies seven mutants that are defective in VIP binding. Biochem Biophys Res Commun 211:901-908
31. Turner PR, Bambino T, Nissenson RA 1996 Mutations of neighboring polar residues on the second transmembrane helix disrupt signalling by the parathyroid hormone receptor. Mol Endocrinol 10:132-139
32. 1B-adrenergic receptor: Potential role of protonation and hydrophobicity of a highly conserved aspartate. Proc Natl Acad Sci USA 94:808-813
33. Gaudin P, Royer-Fessard C, Couvineau A, Maoret J-J, Laburthe M 1996 Characterization of a constitutively active mutant of the human vasocactive intestinal peptide (VIP) 1 receptor. Regul Pept 64:49 (Abstract)
34. Heller RS, Kieffer TJ, Habener JF 1996 Point mutations in the first and third intracellular loops of the glucagon-like peptide-1 receptor alter intracellular signalling. Biochem Biophys Res Commun 223:624-632
35. Tseng CC, Lin L 1997 A point mutation in the glucose-dependent insulinotropic peptide receptor confers constitutive activity. Biochem Biophys Res Commun 232:96-100
36. Kudo M, Osuga Y, Kobilka BK, Hsueh AJW 1996 Transmembrane regions V and VI of the human luteinizing hormone receptor are required for constitutive activation by a mutation in the third intracellular loop. J Biol Chem 37:22470-22478
37. Gardella TJ, Luck MD, Jensen GS, Schipani E, Potts Jr JT, Jüppner H 1996 Inverse agonism of amino-terminally truncated parathyroid hormone (PTH) and PTH-related peptide (PTHrP) analogs revealed with constitutively active mutant PTH/PTHrP receptors. Endocrinology 137:3936-3941
38. Horton RM, Hunt HD, Ho SN, Pullen JK, Pease LR 1989 Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension. Gene 77:51-59
39. Johansen TE, Schøller MS, Tolstoy S, Schwartz TW 1990 Biosynthesis of peptide precursors and protease inhibitors using new constitutive and inducible eukaryotic expression vectors. FEBS Lett 267:289-294
40. 3 (neurokinin B) receptors in transfected CHO cells. FEBS Lett 296:241-244
41. Solomon Y, Londos C, Rodbell M 1974 A highly sensitive adenylate cyclase assay. Anal Biochem 58:541